Search Within

Heiko Schoder

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (39)
  2. Meeting Abstract (28)
  3. Research Letter (3)
  4. Editorial (1)
Groups
  1. Department of Pathology and Laboratory Medicine (71)
  2. Molecular Imaging and Therapy Service (71)
  3. Radiology, Department of (71)
  4. Department of Medicine (58)
  5. Survivorship Research (48)
  6. Solid Tumor Oncology Division (38)

More Groups

People
  1. Ahmet Dogan (23)
  2. Alison Moskowitz (17)
  3. Andrew Zelenetz (17)
  4. Anita Kumar (17)
  5. Paul Hamlin (17)
  6. Gilles Salles (16)

More People

Years
  1. 2025 (3)
  2. 2024 (10)
  3. 2023 (10)
  4. 2022 (3)
  5. 2021 (8)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Blood (8)
  3. European Journal of Nuclear Medicine and Molecular Imaging (6)
  4. International Journal of Radiation Oncology, Biology, Physics (5)
  5. Annals of Surgical Oncology (4)
  6. Hematological Oncology (3)

More Publications

Publishers
  1. Springer (15)
  2. American Society of Clinical Oncology (12)
  3. American Society of Hematology (10)
  4. Elsevier Inc. (6)
  5. Wiley Blackwell (5)
  6. Nature Publishing Group (3)

More Publishers

Results (71)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Batlevi, C. L.; Nos, G.; Kotlov, N.; Sorokina, M.; Okwali, M.; Bagaev, A.; Michaud, L.; Shah, G. L.; Shouval, R.; Tomas, A. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Precision radiotherapy: Reduction in radiation for oropharyngeal cancer in the 30 ROC trial
    Journal Article

    Riaz, N.; Sherman, E.; Pei, X.; Schöder, H.; Grkovski, M.; Paudyal, R.; Katabi, N.; Selenica, P.; Yamaguchi, T. N.; Ma, D.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save